Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia
Onconova Therapeutics, Inc. (ONTX)
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.onconova.com/investor-overview
Company Research
Source: GlobeNewswire
Rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood countsPatients with response or stable disease had one year longer survival than non-respondersRigosertib was well tolerated and a recommended dose for further evaluation was established NEWTOWN, Pa., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the publication of results from a Phase 1/2 study of rigosertib intravenous in patients with MDS and MDS which progressed to Acute Myeloid Leukemia (AML) in the journal, Leukemia Research. In the study, rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood counts, and patients with response or stable disease had one year longer survival than non-responders. This study was conducted at the Mount Sinai
Show less
Read more
Impact Snapshot
Event Time:
ONTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONTX alerts
High impacting Onconova Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONTX
News
- Traws Pharma Announces New Employee Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Announces New Employee Inducement GrantsGlobeNewswire
- Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology CompanyGlobeNewswire
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
ONTX
Earnings
- 11/14/23 - Beat
ONTX
Sec Filings
- 4/4/24 - Form 8-K
- 4/4/24 - Form DEFA14A
- 4/3/24 - Form 4
- ONTX's page on the SEC website